Rapamycin users lived no longer in an 11-year study of 11,474 kidney transplant patients

Researchers at NYU Langone Health and the University of Illinois Chicago used US national organ transplant registry data to compare 4,885 kidney transplant recipients prescribed rapamycin with 6,589 recipients who were not. Everyone in the analysis was alive with a functioning graft one year after transplant. Median follow-up was 11 years, and 6,443 people died during the study.

What they found

The team used propensity score weighting to balance the groups on age, body mass index, diabetes and 15 other factors. After adjustment, median survival age was 64.6 years in the rapamycin group and 64.3 years in the comparison group. The 95% confidence interval for the difference ran from 1.6 years shorter to 2.0 years longer, so the authors concluded that mTOR inhibition was not linked to a meaningful improvement in long-term survival.

The nuance

This is an observational study in people taking rapamycin as part of transplant care, not a trial of low-dose rapamycin in healthy older adults. Transplant recipients carry kidney disease and other health burdens that could swamp a modest aging effect. The abstract does not report dose or duration of use, and a null result on survival says little about other healthspan outcomes such as immune function or muscle.

Youthful take

Rapamycin is FDA-approved for transplant and other specific uses. Taking it for aging is off-label and unproven, and it can suppress the immune system. This study is a reason for humility, not a verdict. If you are curious about rapamycin, start with a physician who will weigh your personal risks and the limited human evidence.